Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood blood.2024025154.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Tessa Seale, Brandy Perkins, Theodora Chatzilygeroudi, Soren Cole, Kareem Battah, Maximilian Stahl, Mark J. Levis, Alexander J. Ambinder, Sandra Misale, Theodoros Karantanos

Blood (2024) 144 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2024-211218

Published: 2024

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Blood (2024) 144 (Supplement 1): 848.

https://doi.org/10.1182/blood-2024-203303

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

Rithin Nedumannil, Chelsea Matley, Ashish Bajel, Mark J. Levis, Andrew H Wei

Blood (2024) 144 (Supplement 1): 6060.

https://doi.org/10.1182/blood-2024-194547

Published: 2024

Journal Articles

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

Arshia Arora, Hua-Ling Tsai, Venkata Preetam Sandeep Kaduluri, Mark J. Levis, Alexander J. Ambinder

Blood (2024) 144 (Supplement 1): 6171.

https://doi.org/10.1182/blood-2024-211081

Published: 2024

Journal Articles

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

Alexander J. Ambinder, Mark J. Levis, Xin Wang, Keith W. Pratz, Andrew H Matthews

Blood (2024) 144 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2024-207062

Published: 2024

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Mark J. Levis, Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Li Liu, Yasser M. Mostafa Kamel, Karima Imadalou, Abderrahmane Laadem, Mikkael A. Sekeres, Kristy Burns

Blood (2024) 144 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2024-207305

Published: 2024

Journal Articles

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Alexander E. Perl, Mark J. Levis, Andrew Wei, Hee-je Kim, June-won Cheong, Yu Zhang, Jian Li, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Jamie Jung-Hee An, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2024-204831

Published: 2024

Journal Articles

Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3 -ITD-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML)

Jaime E. Connolly Rohrbach, Edward Waldron, Li Liu, Shawn Rivera, Sridevi Kayyur Subramanya, Violet Abraham, Alexander E. Perl, Mark J. Levis

Blood (2024) 144 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2024-201727

Published: 2024

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Ruiqi Zhu, Courtney Shirley, Haihua Chu, Li Li, Bao Nguyen, Jaesung Seo, Tessa Seale, Amy Duffield, Louis M. Staudt, Mark J. Levis, Yu Hu, Donald Small

Blood (2023) 142 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2023-190696

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

Tessa Seale, Li Li, J. Kyle Bruner, Bao Nguyen, Mark J. Levis, Christine Pratilas, Donald Small

Blood (2023) 142 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2023-184338

Published: 2023

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk

Blood (2023) 142 (Supplement 1): 972.

https://doi.org/10.1182/blood-2023-186206

Published: 2023

NARROW

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3 -ITD-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML)

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only